Guido Kroemer

This inventor holds 17 USPTO granted patents and 18 published patent applications and 6 EPO patents. Top assignees: Institut Gustave Roussy, National Institute of Health and Medical Research, Assistance Publique - Hopitaux De Paris (Aphp). Active years: 2001-2026.

USPTO Granted Patents = 17 (Patent Applications = 18)

% Patents Active = 47.1

EPO Patents = 6 (Patent Applications = 23)

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 89(Granted Patents)

Location History:

Antony, FR (2012 - 2013)
Paris, FR (2001 - 2024)

Company Filing History:

9 out of 101

Institut Gustave Roussy

patents

8 out of 1,853

National Institute of Health and Medical Research

patents

4 out of 77

Assistance Publique - Hopitaux De Paris (Aphp)

patents

4. 4 out of 5,383

Centre National De La Recherche Scientifique

Universite Paris Cité

patents

8. 2 out of 15

Université De Technologie De Compiègne

Ceinge Biotecnologie Avanzate Scarl

patent

11. 1 out of 1

Instit National De La Sante Et De Al Recherche Medicale (Inserm)

patent

12. 1 out of 1

Instituto Nazionale Per Le Malattie Infettie Irccs Lazzaro Spallanzani

patent

13. 1 out of 132

Université Paris Descartes

Université Pierre Et Marie Curie

patents

16. 1 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12644156 - Methods for diagnosing, prognosing and managing treatment of breast cancer (2026-06-02),

2. 12343376 - Methods for inhibiting diazepam binding protein (2025-07-01),

3. 11905330 - Methods for weight reduction (2024-02-20),

4. 11040052 - Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof (2021-06-22),

5. 10969380 - Simultaneous detection of cannibalism and senescence as prognostic marker for cancer (2021-04-06),

6. 9938528 - Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections (2018-04-10),

7. 9726661 - Simultaneous detection of cannibalism and senescence as prognostic marker for cancer (2017-08-08),

8. 8865653 - Method of treatment for immunogenic treatment resistant cancer (2014-10-21),

9. 8828944 - Compounds and uses thereof to induce an immunogenic cancer cell death in a subject (2014-09-09),

10. 8557517 - Toll like receptor 4 dysfunction and the biological applications thereof (2013-10-15),

11. 8263344 - Compounds regulating calreticulin, KDEL receptor and/or Erp-57 cell surface exposure and uses thereof to evaluate the efficiency of a cancer treatment (2012-09-11),

12. 8129340 - Inhibitors of protein phosphatase 1, GADD34 and protein phosphatase 1/GADD34 complex, preparation and uses thereof (2012-03-06),

13. 7642051 - Screening methods for the identification of inhibitors of human immunodeficiency virus (HIV) viral protein R (Vpr) binding to the adenine nucleotide translocator (ANT) (2010-01-05),

14. 7371834 - Apoptosis-inducing factor (2008-05-13),

15. 7056735 - Mimetics and inhibitors of the interaction between Vpr (HIV viral protein of regulation) and ANT (Mitochondrial adenine nucleotide translocator) (2006-06-06),

Title: Innovator Spotlight: Guido Kroemer - Pioneering Autophagy Modulation for Weight Reduction

Introduction: Guido Kroemer, a renowned inventor based in Paris, FR, has made significant contributions to the field of autophagy modulation for weight reduction. With 15 patents to his name, Kroemer's groundbreaking research has paved the way for novel methods in the treatment of various diseases by targeting autophagy pathways.

Latest Patents: Kroemer's latest patents focus on methods for weight reduction through the modulation of autophagy. By identifying the role of diazepam binding inhibitor (DBI) in regulating autophagy, Kroemer and his team have developed pharmaceutical compositions for modulating autophagy in individuals requiring such treatment. Their research demonstrates the potential of DBI inhibition in enhancing glycolysis, lipogenesis, and metabolic changes that lead to weight loss.

Career Highlights: Kroemer has held key positions at prestigious institutions such as Institut Gustave Roussy and Centre National De La Recherche Scientifique. His dedication to advancing the understanding of autophagy and its therapeutic implications has earned him recognition in the scientific community.

Collaborations: Kroemer has collaborated with esteemed colleagues including Laurence Zitvogel and Jean-Luc Perfettini. Through collaborative efforts, Kroemer has been able to broaden the scope of his research and develop innovative solutions to complex medical challenges.

Conclusion: Guido Kroemer's pioneering work in autophagy modulation stands as a testament to his ingenuity and commitment to improving healthcare outcomes. His patents and research have significantly advanced the field of weight reduction and opened new avenues for treating autophagy-related diseases.